Enasidenib

1:27
Progress in AML & research at the University of Düsseldorf
Thomas Schröder
4:31
Personalized AML therapy with John Byrd: the beat AML trial and more
John Byrd
2:52
Ivosidenib or enasidenib with chemotherapy for AML produces deep remissions
Eytan Stein
2:25
Beat AML: promising results with enasidenib for AML in the frontline
Eytan Stein
1:25
IDH inhibitors for AML: highlights from ASH 2018
Marina Konopleva
1:51
IDH1/2 inhibitors for upfront AML therapy and transfusion independence
Amir Fathi
4:42
Gene-based treatments show positive outcomes in AML
Harry Erba
4:06
Gene-targeting therapies for AML
Harry Erba
1:53
The promising role of IDH inhibitors in AML
Amir Fathi
3:29
Novel drugs and targets in MDS
Valeria Santini
2:13
A success story: IDH inhibitors for AML
Alexander Perl
3:51
Changes in the AML treatment landscape
Richard Stone
4:14
Future therapies for AML: bispecifics and small molecule inhibitors
Farhad Ravandi
1:32
IDH inhibitors for AML and MDS
Eunice Wang
2:56
Newly approved drugs for AML in the US
Naval Daver
3:16
AML metabolism may be the key to successful treatment
Giovanni Martinelli
VJHemOnc VJHemOnc is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

VJHO needs the contact information you provide to inform you about our latest hemonc news and videos, educational courses and industry supported content (some of which may be promotional in nature). You may unsubscribe from these communications at anytime. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy.

The content of VJHemOnc is intended for healthcare professionals